The use of pharmacologic agents in atherosclerosis therapy.
D000818:Animals; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000188:drug therapy*; D002087:Butyrates / Q000009:adverse effects / Q000627:therapeutic use; D002219:Carbamates / Q000627:therapeutic use; D002776:Cholestanes / Q000627:therapeutic use; D002792:Cholestyramine Resin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004967:Estrogens / Q000009:adverse effects / Q000627:therapeutic use; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D009355:Neomycin / Q000009:adverse effects / Q000627:therapeutic use; D009539:Nicotinic Acids / Q000009:adverse effects / Q000627:therapeutic use; D013237:Stereoisomerism; D013261:Sterols / Q000627:therapeutic use; D013974:Thyroxine / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D002087:Butyrates; D002219:Carbamates; D002776:Cholestanes; D004967:Estrogens; D009539:Nicotinic Acids; D013261:Sterols; D002792:Cholestyramine Resin; D006493:Heparin; D009355:Neomycin; D013974:Thyroxine